Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Adv Exp Med Biol. 2019;1152:217-228. doi: 10.1007/978-3-030-20301-6_10.
Trastuzumab represents the predominant therapy to target breast cancer subtype marked by HER2 amplification. It has been in use for two decades and its continued importance is underlined by recent FDA approvals of its biosimilar and conjugated versions. Progression to an aggressive disease with acquisition of resistance to trastuzumab remains a major clinical concern. In addition to a number of cellular signaling pathways being investigated, focus in recent years has also shifted to epigenetic and non-coding RNA basis of acquired resistance against trastuzumab. This article provides a succinct discussion on the most recent advances in our understanding of such factors.
曲妥珠单抗是针对 HER2 扩增型乳腺癌亚型的主要治疗药物。它已经使用了二十年，其生物类似药和缀合物版本最近获得 FDA 批准，这突显了它的持续重要性。对曲妥珠单抗产生耐药性并进展为侵袭性疾病仍然是一个主要的临床关注点。除了研究许多细胞信号通路外，近年来的重点也转移到了曲妥珠单抗获得性耐药的表观遗传和非编码 RNA 基础上。本文简要讨论了我们对这些因素的最新认识。
